Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT06254001

Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects

Led by National Institute of Respiratory Diseases, Mexico · Updated on 2024-02-23

134

Participants Needed

1

Research Sites

126 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In the 20th century, tobacco caused the death of 100 million people worldwide and it is estimated that it will be responsible for 1 billion deaths in the 21st century. Currently 8 million people die each year from smoking, 7 million are associated with active smoking, thus being the main risk factor for loss of disability-adjusted life years for men and the ninth most important risk factor for women. In previous studies it has been reported that approximately 21% (14%-30%) of subjects who have required hospitalization are active smokers, being higher in men than in women (28% vs 14%). The initiation of treatment for smoking cessation in this group of subjects has shown an effectiveness rate of up to 65% to maintain abstinence 6 to 12 months after discharge. The effectiveness has been analyzed in scenarios with only brief advice, in some others with the use of medications such as varenicline, bupropion and nicotine replacement therapy, however, the interventions have not been standardized for adequate analysis, which could contribute to the different results.

CONDITIONS

Official Title

Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years or older
  • Active smokers (more than 100 cigarettes in their lifetime and smoked in the last 30 days)
  • Currently hospitalized
  • Able to provide informed consent
Not Eligible

You will not qualify if you...

  • Used medication to stop smoking in the past month
  • Have contraindications for the study medications

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Instituto Nacional de Enfermedades Respiratorias

Mexico City, Mexico, 14080

Actively Recruiting

Loading map...

Research Team

I

IRERI THIRION, DR

CONTACT

R

ROGELIO PEREZ-PADILLA, DR

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here